Enovis Corporation (ENOV)
| Market Cap | 1.25B -31.5% |
| Revenue (ttm) | 2.28B +6.0% |
| Net Income | -1.14B |
| EPS | -19.88 |
| Shares Out | 57.56M |
| PE Ratio | n/a |
| Forward PE | 5.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 907,673 |
| Open | 20.99 |
| Previous Close | 21.12 |
| Day's Range | 20.65 - 21.88 |
| 52-Week Range | 20.55 - 36.82 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 43.00 (+97.25%) |
| Earnings Date | May 7, 2026 |
About ENOV
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary ca... [Read more]
Financial Performance
In 2025, Enovis's revenue was $2.25 billion, an increase of 6.66% compared to the previous year's $2.11 billion. Losses were -$1.18 billion, 43.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ENOV stock is "Strong Buy." The 12-month stock price target is $43.0, which is an increase of 97.25% from the latest price.
News
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient c...
Enovis Transcript: AGM 2026
The meeting, held virtually, saw all director nominees elected and all proposals approved by majority vote. No questions were raised by stockholders, and final results will be posted online and filed with regulators.
Enovis price target raised to $36 from $35 at Evercore ISI
Evercore ISI raised the firm’s price target on Enovis (ENOV) to $36 from $35 and keeps an Outperform rating on the shares.
Enovis price target lowered to $37 from $45 at Baird
Baird analyst Jeffrey Johnson lowered the firm’s price target on Enovis (ENOV) to $37 from $45 and keeps an Outperform rating on the shares. The firm updated its model following…
Enovis Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% sales growth, strong execution in both segments, and robust innovation momentum. Adjusted EPS rose 10% year-over-year, with margin improvement and reaffirmed 2026 guidance despite macro and cost headwinds.
Enovis Earnings release: Q1 2026
Enovis released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Enovis Slides: Q1 2026
Enovis has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Enovis Quarterly report: Q1 2026
Enovis has published its Q1 2026 quarterly earnings report on May 7, 2026.
Enovis reports Q1 adjusted EPS 89c, consensus 81c
Reports Q1 revenue $589M, consensus $572.44M. “Our first-quarter results reflect solid execution and continued progress advancing our innovation-led strategy,” said Damien McDonald, Chief Executive Of...
Enovis backs FY26 adjusted EPS view $3.52-$3.73, consensus $3.63
Enovis (ENOV) reaffirms financial expectations for 2026. Revenue is expected to approximate $2.31B-2.37B, which incorporates 4-6% organic revenue growth, consensus $2.34B. Adjusted EBITDA is expected ...
Enovis Announces First Quarter 2026 Results
Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results...
Enovis assumed with an Outperform at William Blair
William Blair assumed coverage of Enovis (ENOV) with an Outperform rating. The firm believes the stock’s valuation reflects investor skepticism. Enovis’ execution on free cash flow improvement will be...
Enovis price target lowered to $39 from $43 at BTIG
BTIG lowered the firm’s price target on Enovis (ENOV) to $39 from $43 and keeps a Buy rating on the shares as part of a broader research name on Medical…
Enovis to Host First Quarter 2026 Results Conference Call on May 7th
Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and li...
Enovis price target lowered to $35 from $36 at Evercore ISI
Evercore ISI lowered the firm’s price target on Enovis (ENOV) to $35 from $36 and keeps an Outperform rating on the shares as part of the firm’s medical technology and…
Enovis Proxy statement: Proxy filing
Enovis filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Enovis Proxy statement: Proxy filing
Enovis filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Enovis assumed with an Overweight at Wells Fargo
Wells Fargo assumed coverage of Enovis (ENOV) with an Overweight rating and $42 price target The firm is maintaining the current rating, price target and estimates.
Enovis Transcript: 2026 CG Musculoskeletal Conference
Solid 2025 growth was driven by double-digit gains in extremities and international recon, increased R&D investment, and successful integration of acquisitions. New technology launches, especially in ARVIS and hip products, are set to drive further growth in 2026, with strong momentum in ASCs and international markets.
Enovis participates in a conference call with JPMorgan
Medical Supplies & Devices Equity Analyst Marcus discusses 4Q earnings with Investor Relations Kyle Rose on a conference call to be held on February 27 at 12 pm hosted by…
Enovis Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 7% sales growth, margin expansion, and positive free cash flow. 2026 guidance calls for 4–6% organic growth, higher margins, and a step-up in free cash flow conversion, supported by robust innovation and disciplined capital allocation.
Enovis Annual report: Q4 2025
Enovis has published its Q4 2025 annual report on February 26, 2026.
Enovis Earnings release: Q4 2025
Enovis released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Enovis Slides: Q4 2025
Enovis has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and...